FDA shakes up weight loss market
Yahoo · 3d
Knockoff weight loss drug sellers are fighting back against Eli Lilly and the FDA
Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss drugs during widespread shortages to halt production now that supplies are stabilizing.
Ars Technica · 4d
Drug makers can’t make knockoff weight-loss drugs anymore—and they’re mad
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to the drug makers, writing in bold that the agency "reminds compounders of the legal restrictions on making copies of FDA-approved drugs."
devdiscourse · 2d
FDA Reconsiders Sale of Compounded Diabetes and Weight Loss Drugs
The FDA has decided to reconsider its previous decision that barred drug compounders from selling their versions of Eli Lilly's weight loss and diabetes drugs. This comes after a lawsuit by the Outsourcing Facilities Association.
Benzinga.com · 5d
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment.
Benzinga.com · 3d
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, Mounjaro and Zepbound, after the FDA declares the tirzepatide shortage resolved.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results